



## The Regulation of JAKs in Health and in Disease

Guest Editors:

**Dr. Bobin George Abraham**

Faculty of Medicine and Health  
Technology, Tampere University,  
Tampere, Finland

**Dr. Anniina T. Virtanen**

Faculty of Medicine and Health  
Technology, Tampere University,  
Tampere, Finland

Deadline for manuscript  
submissions:

**closed (15 May 2022)**

### Message from the Guest Editors

JAK kinases mediate signaling from approximately 60 cytokines and hormones in the regulation of hematopoiesis, metabolism, inflammation, and immune response. The activation of JAKs functions as the triggering signal for all cytokine signaling where STAT transcription factors are the prototypical substrates and the crosstalk between different signaling pathways underlie the appropriate cellular regulation and biological responses.

This Special Issue will focus on the most recent advances in the regulation of JAKs in cytokine signaling and in diseases and emerging therapeutic approaches. We invite original research articles, short communications, and reviews from basic science to case studies and clinical trials on topics including but not limited to the following:

Regulation of JAKs; JAK-STAT signaling; JAKs in hematological, inflammatory, and autoimmune diseases; Identification and characterization of pathogenic JAK mutations; JAK inhibitors: Methodology for assessment of biochemical features, efficacy or safety, development of novel inhibitors, pre-clinical studies, and clinical findings.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)  
[X@Pharmaceut\\_MDPI](https://twitter.com/Pharmaceut_MDPI)